The fluctuations of serum lipid and lipoprotein concentrations within one cycle were studied both in women using and not using oral contraceptives. High-density lipoprotein cholesterol decreased significantly from 1 47 mmol/l (57 mg/100 ml) to 1 30 mmol/l (50 mg/100 ml) during one contraceptive cycle in eight women and rose again to the initial value during the pill-free days. The mean concentration of total cholesterol also fell significantly as a result of the decrease of high-density lipoprotein cholesterol and of a not significant decrease of low-density lipoprotein cholesterol. The mean serum triglyceride concentration did not change significantly. The fluctuations in the concentration of serum lipids and lipoproteins in 10 women not using oral contraceptives were smaller than in the women using oral contraceptives and no significant changes in the concentrations were found during one cycle.
Introduction
Epidemiological studies have shown a relationship between the use of oral contraceptives and an increased incidence of cardiovascular diseases.1 2 Furthermore, oral contraceptives appear to influence the concentrations of serum lipids and lipoproteins.3 4 Since these concentrations are related to the risk of coronary heart disease,5 precise knowledge of the effect of oral contraceptives is of the utmost importance.
The effect of oral contraceptives on high-density lipoprotein cholesterol is a particularly controversial subject, probably because of the qualitative and quantitative differences between the many formulations of drug combinations in use.6 7 Moreover, in most of these studies blood samples were taken on random days of the contraceptive cycle. Furthermore, the concentrations of serum lipids and lipoproteins were assumed to be more or less constant during one cycle. This has, however, never been proved. We therefore studied possible changes in the concentrations of serum lipids and lipoproteins during one contraceptive cycle in women using oral contraceptives and also during one menstrual cycle in women not using them.
Subjects and methods
The 18 women participating in this study were healthy hospital employees with body weights within 10% of the norm.8 Eight women (mean age 27; range 22-36 years) had been using oral contraceptives for at least six months; these contained either 125-150 jzg levenorgestrel (two women) or 250 Isg levenorgestrel (six women), both combined with 50 jig ethinyloestradiol, and were taken for 21 consecutive days out of 28. The other 10 women (mean age 30, range 24-37 years) did not use oral contraceptives. They had regular menstrual cycles (mean, 28 days; range, 24-32 days).
Blood samples were collected after an overnight fast under standardised conditions without stasis. In women using oral contraceptives blood samples were obtained twice weekly during one contraceptive cycle from six and only once weekly from two. In all these women the first blood sample was obtained on the first day of the contraceptive cycle. In women not using oral contraceptives, blood samples were obtained twice weekly during one menstrual cycle from seven and only once weekly in three. In all these women the first blood sample was obtained on the second day of the menstrual cycle. In both groups of women the values at the start of the succeeding cycle were also determined.
The contraceptive cycle was arbitrarily divided into four equal periods and the results between days 2-8, 9-15, 16-22, and 23-28 were compared with those on the first day of the cycle. The cycles of various lengths in the women not using the contraceptive pill were divided into four periods representing the menstrual, follicular, ovulatory, and luteal phases.9 As the second period started on the third day of the menstrual cycle only one value was available for the first period. When more than one value was obtained for a given period for an individual woman, the mean of both samples was taken.
Serum was separated by centrifugation 2-3 h after blood sampling, stored at 4°C, and analysed within six days. Cholesterol was determined with the enzymic catalase reagent and triglycerides by semiautomated colorimetry.'0 High-density lipoprotein was determined with the heparin/Mn2+ precipitation method; the high-density lipoprotein fraction was isolated at 12 000 xg."0'" Low-density lipoprotein cholesterol, expressed in mmol/l, was calculated according to the Friedewald formula: low-density lipoprotein-cholesterol = total cholesterol -(high-density lipoprotein-cholesterol + 0-46 x triglyceride Cotnversion: SI to traditional units-Cholesterol: 1 mmol/l139 mg/100 ml. Triglyceride: 1 mmol/l z 90 mg/100 ml. compared with the mean results on the first day of two contraceptive cycles and on the second day of menstruation of two menstrual cycles (see table) . In women using oral contraceptives high-density lipoprotein cholesterol decreased during the contraceptive cycle from 1 47 mmol/l (57 mg/100 ml) to 1 30 mmol/l (50 mg/100 ml) (p < 0-05) and rose again to the starting value during the pill-free days. Total serum cholesterol concentrations also fell significantly during the cycle (maximum 0 40 mmol/l, p < 0 05) as a result of the decrease in high-density lipoprotein cholesterol and a not significant decrease in low-density lipoprotein cholesterol. Concentrations of triglycerides did not change significantly.
In women not using oral contraceptives no significant changes in the concentrations of cholesterol, triglycerides, low-density and highdensity lipoprotein cholesterol were found during one cycle. For all the serum lipids and lipoproteins measured, the absolute differences in the individual subjects within one cycle between the highest and lowest mean concentrations of each cycle were more than twice as great in the women using oral contraceptives as in the non-users. The same was true for the fluctuations in the mean concentrations of the two groups (see table) .
Discussion
Our data indicate that the moment of blood sampling during the contraceptive cycle is of vital importance in interpreting the concentrations of high-density lipoprotein cholesterol in women using oral contraceptives. We observed a tendency to lower high-density lipoprotein cholesterol concentrations after 2-8 days and significantly lower values after 9-22 days compared with those on the first day of the contraceptive cycle (p <005). The effects of oral contraceptives on high-density lipoprotein cholesterol concentrations in women have been confused by the different types and combinations of doses of oestrogens and progestogens. 6 In those studies in which high-density lipoprotein cholesterol values were similar to those of non-users or to control values in the same subjects,1' 16 blood had been sampled on random days during the cycle. Decreased highdensity lipoprotein cholesterol concentrations in users of the contraceptive pill have also been found7 17-19; in three of these studies blood was sampled around the twenty-first day of the contraceptive cycle. Thus, not only the type of composition of the oral contraceptive pill but also the time of blood sampling during the cycle is important in obtaining lower high-density lipoprotein cholesterol values.
We also noticed lower low-density lipoprotein cholesterol values during the contraceptive cycle which tended to be significant in period 1. Similar or increased low-density lipoprotein cholesterol concentrations have been found compared with pretreatment values in women using different types of oral contraceptives.4 7 13
The fluctuations in high-density and low-density lipoprotein cholesterol in a normal menstrual cycle do not apparently show a clear pattern. The intraindividual variations in concentrations of cholesterol, triglycerides, and high-density lipoprotein cholesterol are, however, quite great. To obtain an accurate estimate in one individual, three determinations should be done if possible (unpublished observations). In our study only one value for each subject was available in the first period whereas for both groups of women an average of 1-7 and 1-8 measurements were recorded in the other periods. Thus, the values in the first period were less accurate. We therefore compared the results obtained during one cycle with the mean of both first periods and concluded that total concentrations of cholesterol and of low-density and high-density lipoprotein cholesterol during one cycle did not change significantly in women not using oral contraceptives. Other studies have shown a cyclical rise during the normal menstrual cycle, with the highest total cholesterol concentrations occurring at the ovulatory phase.9 20 Nevertheless, a cyclical decrease in total cholesterol, with the lowest values in the ovulatory or the luteal phases, has also been found." " Slight but insignificant variations in low-density lipoprotein cholesterol concentrations during the cycle have also occurred." High-density lipoprotein cholesterol concentrations have increased during the cycle," " with significantly higher concentrations of HDL2 at ovulation and a decrease as menstruation approached. Thus published data are not consistent. These apparently conflicting results can, at least partly, be ascribed to the large variability in concentrations of serum lipids and highdensity lipoprotein cholesterol in women ( results not yet published) and to the different groups of women studied. Our data show that in a group of hospital employees using oral contraceptives the fluctuations in the concentrations at each cycle period were slight and more than twice as small as in the women using oral contraceptives. Thus, in these women the time of blood sampling within one menstrual cycle was less important than in women who used oral contraceptives.
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Correspondence should be addressed: Dr P N M Demacker, Department of Internal Medicine, St Radboud Hospital, Geert Grooteplein Zuid 8, 6500 HB Nijmegen, The Netherlands. Introduction Several groups, including our own, have shown that the production of prostacyclin (PGI2) by aortas from diabetic rats is diminished.'-6 As PGI2 is a potent inhibitor of platelet aggregation,7 the deficiency in production of PGI2 may contribute to the high incidence of vascular disease in diabetes. The relevance of these findings in diabetic rat aortas has been challenged by reports showing no decrease in circulating 6-oxo-prostaglandin Floc (6-oxo-PGF,cx) (the stable metabolite of PGI2) in human diabetes.8 19 This suggests either that the observations in diabetic rats are not relevant to human diabetes or that regional differences in PGI2 production occur. In particular there might be differences in PGI2 production between large arteries and the microvascular circulation. We have tested this second possibility by measuring the production of 6-oxo-PGF,cx by glomeruli and aortas from the same group of diabetic rats.
Animals and methods
Diabetes was induced in nine age-matched male Sprague-Dawley rats (weight about 250 g) as described.6 Between 31 and 41 days after intravenous injection of streptozocin 60 mg/kg, one streptozocin-
